|Bid||59.111 x 100000|
|Ask||59.175 x 100000|
|Day's Range||59.011 - 59.605|
|52 Week Range||50.112 - 63.309|
|PE Ratio (TTM)||37.61|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This cancer drug produced data so incredible that the FDA approved it immediately for a specific genetic mutation, regardless of cancer location.
The Merck collab would count as Leap's first of planned studies with immunotherapies, but the collaboration is not Keytruda's first rodeo.
Merck is extending this week's impressive rally and will soon retest the 2017 highs.